Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Boehringer Ingelheim v. Mylan Pharmaceuticals Inc., No. 19-1172 (Fed. Cir. Mar. 16, 2020)

Reversed in Part
§ 101 Eligibility Invalidity (§ 102/§ 103)
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 19-1172
Decided
March 16, 2020
Judge
Moore, J.
Document
Nonprecedential Opinion
Length
11 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Appellants Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, and Boehringer Ingel- heim Pharma GmgH & Co. KG (collectively, Boehringer) sued Mylan Pharmaceuticals Inc., Mylan Inc., Mylan La- boratories, Ltd. , Aurobindo Pharma Limited and Auro- bindo Pharma USA, Inc. (collectively, Appellees) for infringement of U.S. Patent Nos. 8,853,156, 9,173,859 and 8,673,927, which relate to the treatment of type 2 diabetes mellitus with DPP -IV inhibitors such as linagliptin .

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error